Zydus Cadila has received the tentative approval from the USFDA to market Lacosamide Tablets (US RLD - Vimpat®) in the strengths of 50 mg, 100 mg, 150 mg and 200 mg. Lacosamide is an anticonvulsant or antiepileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain. The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has 261 approvals and has so far filed over 350 ANDAS since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.344.75 as compared to the previous close of Rs. 344.15. The total number of shares traded during the day was 37002 in over 707 trades.
The stock hit an intraday high of Rs. 348.8 and intraday low of 343.25. The net turnover during the day was Rs. 12788349.